NewLink Genetics to Participate in Upcoming Investor Conference
November 27 2017 - 9:24AM
NewLink Genetics Corporation (NASDAQ:NLNK) will participate in
the Global Mizuho Investor Conference on Tuesday, December
5th, in New York City. The format of the conference is
one-on-one meetings with investors only.
About NewLink Genetics
Corporation
NewLink Genetics is a late-stage
biopharmaceutical company focusing on discovering, developing and
commercializing novel immuno-oncology product candidates to improve
the lives of patients with cancer. NewLink Genetics' IDO
pathway inhibitors are designed to harness multiple components of
the immune system to combat cancer. Indoximod is being
evaluated in combination with treatment regimens including
anti-PD-1/PD-L1 agents, cancer vaccines, and chemotherapy across
multiple indications such as melanoma, pancreatic cancer and other
malignancies. For more information, visit
www.newlinkgenetics.com, and follow us on Twitter
@NLNKGenetics.
Investor Contact:Lisa MillerDirector of Investor
RelationsNewLink Genetics(515) 598-2555lmiller@linkp.com
Media Contact:Vivian NiPublic & Media
RelationsLaVoieHealthScience617-374-8800, ext.
109vni@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024